Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(1)

1 unique interventions1 categories

Analytics

Trial Phases

Phase 41

Trial Status

Other1

Role Distribution

Principal Investigator1

PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT07652814Phase 4Active Not Recruiting

Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years

Glycogen Storage Disease Type II Late OnsetPompe DiseasePompe Disease Late-Onset+1 more

PrincipalinvestigatorStart date: 2022-10-13

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Glycogen Storage Disease Type II Late Onset1 Glycogen Storage Disease Type II1 Pompe Disease Late-Onset1 Pompe's Disease Juvenile Onset1

Affiliations

Erasmus Medical Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Regina Trollmann, MD

University Hospital Erlangen

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-OnsetPompe's Disease Juvenile Onset

Similarity Score23%

Ferdinand Knieling, MD

University Hospital Erlangen

2 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-OnsetPompe's Disease Juvenile Onset

Similarity Score23%

Paolo Banfi, MD

IRCCS Fondazione Don Carlo Gnocchi

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Similarity Score15%

Nadine A.M.E. van der Beek, Dr.

Erasmus Medical Center

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Similarity Score15%

Mark Tarnopololsky, MD/PhD

McMaster University

2 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIGlycogen Storage Disease Type II Late Onset

Similarity Score15%

Priya Kishnani, MD

Duke University

8 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Worked with same sponsors:

Sanofi

Similarity Score15%

Tim Preijers, Dr.

Erasmus Medical Center

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Similarity Score15%

Tahseen Mozaffar, MD

University of California Irvine Health

2 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Similarity Score15%

Pieter A. van Doorn, Prof. dr.

Erasmus Medical Center

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type IIPompe Disease Late-Onset

Similarity Score15%

Priya Kishnani

Duke University

1 trials

Shared therapeutic areas:

Glycogen Storage Disease Type II

Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT07652814Phase 4PrincipalInvestigator

Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years

Glycogen Storage Disease Type II Late OnsetPompe DiseasePompe Disease Late-Onset+1 more

Active Not Recruiting

All 1 trials loaded